Differential effects of IL-6 blockade tocilizumab and TNF inhibitors on angiogenesis in synovial tissues from patients with rheumatoid arthritis

References

• Tak PP. Examination of the synovium and synovial fluid. In: Firestein GS, Panayi GS, Wollheim RA, eds. Rheumatoid arthritis: frontiers on pathogenesis and treatment. New York: Oxford University Press; 2000:55–68.
   Google Scholar
• Hirohata K, Kobayashi I. Fine structures of the synovial tissues in rheumatoid arthritis. Kobe J Med Sci. 1964;10:195–225.
   PubMedGoogle Scholar
• Burmester GR, Locher P, Koch B, Winchester RJ, Dimitriu-Bona A, Kalden JR, et al. The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol Int. 1983;3:173–81.
   PubMed Web of Science ®Google Scholar
• Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 1996;39:1781–90.
   PubMed Web of Science ®Google Scholar
• Thomas R, Davis LS, Lipsky PE. Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol. 1994; 152:2613–23.
   PubMed Web of Science ®Google Scholar
• Kyogoku M, Sawai T, Murakami K, Ito J. Histopathological characteristics of rheumatoid arthritis - as a clue to elucidate its pathogenesis. Nippon Rinsho. 1992;50:483–9.
   PubMedGoogle Scholar
• Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 1998;41:951–62.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Sakakibara J. Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet. 1999; 353:1331.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–96.
   PubMed Web of Science ®Google Scholar
• Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res. 2002;4(Suppl 2):S22–S8.
   PubMedGoogle Scholar
• Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244–79.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Tomita T, Yoshikawa H, Kyogoku M. TNF inhibitors induce discoid fibrosis in the sublining layers of the synovium with degeneration of synoviocytes in rheumatoid arthritis. Rheumatol Int. 2013;33:2473–81.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2009;19:273–82.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Yanagida T, Nampei A, Kunugiza Y, Hashimoto H, Tomita T, et al. Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial neovascularization. Arthritis Rheum. 2004;50:3888–96.
   PubMed Web of Science ®Google Scholar
• Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, Haupl T. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology. 2006;49:358–64.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, Yachie A. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–94.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Sivridis E, Athanassou N, Zois E, Thorpe PE, Brekken RA, et al. The angiogenic pathway ‘vascular endothelial growth factor/flk-1(KDR)-receptor’; in rheumatoid arthritis and osteoarthritis. J Pathol. 2001;194:101–8.
   PubMed Web of Science ®Google Scholar
• Tas SW, Maracle CX, Balogh E, Szekanecz Z. Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol. 2016;12:111–22.
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Chen Z, Volin MV, Ravella S, Virupannavar S, Shahrara S. The pathogenic role of angiogenesis in rheumatoid arthritis. Angiogenesis. 2015;18:433–48.
   PubMed Web of Science ®Google Scholar
• Izquierdo E, Cañete JD, Celis R, Santiago B, Usategui A, Sanmartí R, et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One. 2009;4:e8131.
   PubMed Web of Science ®Google Scholar
• Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013;23:440–9.
   PubMed Web of Science ®Google Scholar
• Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009;15:5426–34.
   PubMed Web of Science ®Google Scholar
• Yoo AR, Chung SK. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits. Cornea. 2014;33:1088–94.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int. 2009;29:1449–54.
   PubMed Web of Science ®Google Scholar
• Tono T, Aihara S, Hoshiyama T, Arinuma Y, Nagai T, Hirohata S. Effects of anti-IL-6 receptor antibody on human monocytes. Mod Rheumatol. 2015;25:79–84.
   PubMed Web of Science ®Google Scholar
• Shoji M, Furuyama F, Yokota Y, Omori Y, Sato T, Tsunoda F, et al. IL-6 mobilizes bone marrow-derived cells to the vascular wall, resulting in neointima formation via inflammatory effects. J Atheroscler Thromb. 2014;21:304–12.
   PubMed Web of Science ®Google Scholar
• Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res. 2015;106:365–74.
   PubMed Web of Science ®Google Scholar